Warts and All: Verrica and Torii Team Up to Fund Global Phase 3 Trial of YCANTH for Common Warts May 15, 2024
Ligand Pharmaceuticals Launches Pelthos to Accelerate Commercialization of Zelsuvmi for Molluscum; Appoints New CEO April 3, 2024
Skin Biomarkers May Predict Early Risk of Food Allergies or AD in Infants; Prevention Trial Underway March 29, 2024
Verrica Pharmaceuticals’ YCANTH Receives New Chemical Entity Status, Orange Book Listing From FDA March 26, 2024
